Trial 2O-22-3


PhI-135/ NCI 10445: Phase 1 Dose Escalation and Expansion Study of Tazemetostat in Combination of Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer

Type: Treatment
Phase: Phase I
Status: Open to Accrual
Treatments: Chemotherapy: Systemic, Immunotherapy
Randomized: No
USC Satellite Location: USC Koreatown, USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Jorge Nieva, M.D.
Other Trial Staff:  Kristy Sartor Massopust, Coordinator, Sreebharathy Venkatesh, D.M., Anisa Sandin, Coordinator, Andrew Zeng, Coordinator, Bomi Choi, Coordinator, Marie-Laure Gollier, D.M., Sophia Marmolejo, Coordinator, Sandy Tran, Coordinator, Azucena Vera, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.